press release — tag2 RSS



SENTÉ Appoints Laurent Combredet As President & Chief Executive Officer

SAN DIEGO, February 9, 2016 (GLOBE NEWSWIRE) – SENTÉ, a privately held specialty aesthetics company pioneering the development of differentiated medical grade skincare products based on the science of glycosaminoglycans, today announced the appointment of Laurent Combredet as President and Chief Executive Officer. “Laurent is a well respected and strategic leader in the aesthetics dermatology field and we are excited to leverage his leadership and experience to help take the company to the next level,” said Faheem Hasnain, Chairman of the Board of Directors of SENTÉ. “Laurent is a tremendous addition to SENTÉ and I look forward to his strategic insight as we further position the company to be a major contender in the aesthetics industry.” Mr. Combredet brings to...

Continue reading



Senté Inc., Appoints Mireille Gillings, Ph.D. to Its Board of Directors

Experienced Biopharmaceutical Industry Executive Adds to the Depth of the Company’s Board SAN DIEGO, June 17, 2014 (GLOBE NEWSWIRE) — Sente Inc., a privately held specialty aesthetics company pioneering the development of differentiated skincare products based on the science of glycoproteins, announced today that it has appointed Mireille Gillings, Ph.D. to its Board of Directors. Dr. Gillings is Sente’s sixth director and brings additional biotechnology industry operations and management experience to the Sente Board of Directors.M Dr. Gillings has more than 20 years experience in the biotechnology industry and is a published academic in the field of neuroscience. In 2004 she founded HUYA Bioscience International and has since grown this privately-held company to become the global leader in accelerating the...

Continue reading



Sente, Inc. Raises $2.1M in Series B Equity Financing

Funding to Support Commercial Operations and Additional Line Extensions to Senté’s Portfolio of Differentiated Skincare Products Based on Glycoproteins SAN DIEGO, May 14, 2013 (GLOBE NEWSWIRE) — Senté, Inc., a privately held cosmeceutical company engaged in the development of differentiated skincare products based on glycoproteins, announced today that it has closed its Series-B financing, raising $2.1 million from a combination of new and existing biotechnology investors. This financing provides Senté with a sizable cash balance to fund continued company growth. Proceeds from the financing will help Senté, Inc. expand commercial operations, scale development capabilities, and add additional line extensions to its portfolio of differentiated skincare products. “We are very pleased to see such strong investor interest in our company from...

Continue reading